ClinicalTrials.gg
CompletedNCT01838668Updated Nov 20, 2018

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

A Phase 3 interventional study of Placebo and dimethyl fumarate in Relapsing-Remitting Multiple Sclerosis and Multiple Sclerosis, sponsored by Biogen. Completed at 54 sites in 5 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-11-20.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
5th of 22
225 · median 61
Started
2013
with 1 other
Phase 3
10 of 22
none open now
Registered
6th of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 5th largest by enrollment, is one of 2 that started in 2013, is one of 10 in phase 3, and was the 6th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This is a multicenter study conducted in 2 parts:

The primary objective in Part I of this study is to determine the efficacy of BG00012 (dimethyl fumarate, DMF) on inflammatory brain magnetic resonance imaging (MRI) lesion activity (Gadolinium-enhancing lesions) when compared with placebo from 4 scans performed at Weeks 12, 16, 20, and 24 in participants with Relapsing Remitting Multiple Sclerosis (RRMS) including participants from the Asia-Pacific region.

The secondary objectives in Part I of this study in this study population are to determine whether BG00012, when compared with placebo over 24 weeks, is effective in reducing the cumulative number of new Gadolinium-enhancing lesions from Baseline to Week 24; reducing the number of new or newly enlarging T2 hyperintense lesions on brain MRI scans at Week 24 compared with Baseline.

The primary objective in Part II (open label) of this study is to evaluate the long-term safety profile of BG00012 in eligible participants from Part I.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis
  • Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Inclusion Criteria for Part I:

    • Must have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS).
    • Must have a baseline Expanded Disability Status Scale (EDSS) score between 0.0 and 5.0, inclusive.

Key Inclusion Criteria for Part II:

  • Subjects who participated in and completed Part I per protocol.

Key Exclusion Criteria:

  • Other chronic disease of the immune system, , acute urologic, pulmonary, gastrointestinal disease.
  • Pregnant or nursing women.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
225 participants (actual)

Study arms

  • Placebo comparator
    Part I Placebo

    Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID.

    Drug: Placebo

  • Experimental
    Part I BG00012

    BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID

    Drug: dimethyl fumarate

  • Experimental
    Part II BG00012

    Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.

    Drug: dimethyl fumarate

Interventions

  • DrugPlacebo

    Two placebo capsules orally BID

  • Two dimethyl fumarate 120mg capsules orally BID

    Also known as: BG00012, Tecfidera, DMF

06

What researchers measure

Primary outcomes

  1. Total number of new Gadolinium-enhancing lesions over 4 scans at Weeks 12, 16, 20, and 24.

    Time frame: Part I (Week 24)

  2. Incidence of treatment-emergent adverse events and serious adverse events

    Time frame: Part II (Up to 4.5 years)

Secondary outcomes

  1. Cumulative number of new Gadolinium-enhancing lesions from Baseline to Week 24

    Time frame: Part I (Week 24)

  2. Number of new or newly enlarging T2 hyperintense lesions at Week 24 compared with Baseline

    Time frame: Part I (Week 24)

07

Study locations

54 sites
  • Fakultni nemocnice u sv. Anny v Brne
    Brno, 656 91, Czechia
  • Neurospol, s.r.o.
    Havirov, 736 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Privatni ordinace - neurologie
    Hradec Kralove, 50003, Czechia
  • Nemocnice Jihlava
    Jihlava, 58633, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Fakultni poliklinika VFN
    Praha 2, 128 08, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Krajska zdravotni, a.s. - Nemocnice Teplice, o.z.
    Teplice, 41529, Czechia
  • NHO Asahikawa Medical Center
    Asahikawa-shi, 070-8644, Japan
  • Juntendo University Hospital
    Bunkyo-ku, 113-8431, Japan
  • Chiba University Hospital
    Chiba-shi, 260-8677, Japan
  • Kyushu University Hospital
    Fukuoka-shi, 812-8582, Japan
  • Kanazawa Medical University Hospital
    Kahoku-gun, 920-0293, Japan
  • Saitama Medical Center
    Kawagoe-shi, 350-8550, Japan
  • Kobe University Hospital
    Kobe-shi, 650-0017, Japan
  • National Center Hospital, NCNP
    Kodaira-shi, 187-8551, Japan
  • Kyoto University Hospital
    Kyoto-shi, 606-8507, Japan
  • NHO Utano Hospital
    Kyoto-shi, 616-8255, Japan
  • Iwate Medical University Hospital
    Morioka-shi, 020-8505, Japan
  • Niigata University Medical & Dental Hospital
    Niigata-shi, 951-8520, Japan
  • Irino Clinic, Inc.
    Osaka-shi, 556-0016, Japan
  • Kindai University Hospital
    Osakasayama-shi, 589-8511, Japan
  • Tokyotohokeniryokosya Ebara Hospital
    Ota-ku, 145-0065, Japan
  • NHO Hokkaido Medical Center
    Sapporo-shi, 063-0005, Japan
  • CEReS Sapporo Neurology Clinic
    Sapporo-shi, 065-0021, Japan
  • Tohoku University Hospital
    Sendai-shi, 980-8574, Japan
  • Keio University Hospital
    Shinjuku-ku, 160-8582, Japan
  • Department of Neurosurgery, Tokyo Women's Medical University
    Shinjuku-ku, 162-8666, Japan
  • Osaka University Hospital
    Suita-shi, 565-0871, Japan
  • National Defense Medical College Hospital
    Tokorozawa-shi, 359-8513, Japan
  • Ehime University Hospital
    Toon-shi, 791-0295, Japan
  • Tsukuba University Hospital
    Tsukuba-shi, 305-8576, Japan
  • Yamaguchi University Hospital
    Ube-shi, 755-8505, Japan
  • Tokyo Womens Medical University Yachiyo Medical Center
    Yachiyo-shi, 276-8524, Japan
  • Yokohama City University Hospital
    Yokohama-shi, 236-0004, Japan
  • Yeungnam University Hospital
    Daegu, 42415, Korea, Republic of
  • National Cancer Center
    Gyeonggi-do, 10408, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Copernicus Podmiot Leczniczy Sp. z o.o.
    Gdansk, 80-803, Poland
  • M.A. - LEK A.M.Maciejowscy SC.
    Katowice, 40-571, Poland
  • Nzoz Novo-Med
    Katowice, 40-650, Poland
  • Neuro-Care Gabriela Klodowska
    Katowice, 40-749, Poland
  • MCD Medical
    Krakow, 31-637, Poland
  • Centrum Neurologii K. Selmaj
    Lodz, 90-324, Poland
  • Neurologiczny NZOZ Centrum Leczenia SM
    Plewiska, 62-064, Poland
  • NZOZ "NEURO-KARD", "Ilkowski i Partnerzy" Sp. Partn. Lek.
    Poznan, 61-853, Poland
  • Miedzyleski Szpital Specjalistyczny
    Warszawa, 04-749, Poland
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
08

References and documents

Publications

  • Kondo T, Kawachi I, Onizuka Y, Hiramatsu K, Hase M, Yun J, Matta A, Torii S. Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension. Mult Scler J Exp Transl Clin. 2019 Jul 31;5(3):2055217319864974. doi: 10.1177/2055217319864974. eCollection 2019 Jul-Sep. PubMed 31391949 ↗
  • Saida T, Yamamura T, Kondo T, Yun J, Yang M, Li J, Mahadavan L, Zhu B, Sheikh SI. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. BMC Neurol. 2019 Jan 7;19(1):5. doi: 10.1186/s12883-018-1220-3. PubMed 30616596 ↗
  • Ochi H, Niino M, Onizuka Y, Hiramatsu K, Hase M, Yun J, Matta A, Torii S. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension. Adv Ther. 2018 Oct;35(10):1598-1611. doi: 10.1007/s12325-018-0788-8. Epub 2018 Sep 11. PubMed 30206820 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Jun 2015, 26 months.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 26 months is below that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2013
First posted
Apr 24, 2013
StartActual
Mar 28, 2013
Primary completionActual
Jun 16, 2015
CompletionActual
Sep 4, 2018
Last update
Nov 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01838668
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 24, 2013
Start date
Mar 28, 2013
Primary completion
Jun 16, 2015
Completion
Sep 4, 2018
Last update
Nov 20, 2018

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion